Aethlon Medical Reports Reduced Net Loss, Advances Oncology Study to Final Cohort

summarizeSummary

Aethlon Medical reported a substantial reduction in its net loss and operating expenses for fiscal year 2026, alongside significant clinical progress in its Australian oncology study and a $1.85 million capital raise.

check_boxKey Events · Earnings and Guidance · AEMD

• Fiscal Year-End Financial Results

  Reported a net loss of $7.2 million for fiscal year 2026, a significant reduction from $13.4 million in the prior year. Operating expenses also decreased by 21.9% to $7.3 million.

• Clinical Trial Advancement

  The Australian oncology study for the Hemopurifier advanced into its third and final dosing cohort, with the first participant in Cohort 3 successfully treated.

• Capital Raise

  Subsequent to fiscal year-end, the company raised approximately $1.85 million in net proceeds through its At-The-Market (ATM) program, bolstering its cash position.

• Intellectual Property Expansion

  Strengthened its IP portfolio with new patents issued in the U.S. and Europe covering Hemopurifier applications for coronavirus-related conditions, extending protection into the 2040s.

auto_awesomeAnalysis · AEMD · Industrial Applications And Services

Aethlon Medical's fiscal year-end report shows improved financial discipline with a significant reduction in net loss and operating expenses, which is crucial for a company that previously issued a going concern warning. The successful advancement of its Australian oncology study to the final cohort is a key clinical milestone, demonstrating progress in its core therapeutic development. While the company continues to rely on its At-The-Market program for capital, the $1.85 million raised provides additional runway, addressing immediate liquidity concerns, though the long-term financial stability remains a focus.